Will see if the CC tomorrow will help or not the stock, which needs to close above $1.60 <g>
Introgen to Host Conference Call with Clinical Investigators to Discuss Phase III Data and ADVEXIN Registration Activities
Tuesday July 8, 3:37 pm ET
AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN - News) announced today that it will host a conference call with management and invited clinical experts on Thursday, July 10, 2008 at 3:30 p.m. ET.
Introgen management will discuss its recent ADVEXIN regulatory approval filings and phase III clinical data. In addition, several clinical investigators will be available to respond to questions.
These clinicians to include:
Dr. Jack Roth, inventor of ADVEXIN and professor and Bud Johnson Clinical Distinguished Chair, Department of Thoracic & Cardiovascular Surgery, Section Chief, Thoracic Molecular Oncology, and Director, W.M. Keck Cancer Center for Innovative Cancer Therapies, M.D. Anderson Cancer Center, Houston, TX.
Dr. John Nemunaitis, a principal investigator of Introgen’s phase III study and medical director, Mary Crowley Cancer Research Center at Baylor-Charles A. Sammons Cancer Center, Dallas, TX.
Dr. John Hamm, Medical Director, Louisville Oncology at Norton Healthcare, Louisville, KY.
and Dr. Jarrard Goodwin, Director, Sylvester Comprehensive Cancer Center/University of Miami Hospital and Clinics and Sylvester Professor, Department of Otolaryngology-Head and Neck Surgery.
The call will be held on Thursday, July 10, 2008, at 3:30 p.m. Eastern Time.
The call will be available via Introgen’s Web site at www.introgen.com.
The call may also be accessed by dialing 1-877-493-1228 or 1-706-643-1852, conference ID number 55392696. For those unable to listen to the broadcast live, the call will be archived on Introgen’s website.
Snip
Bernard |
